View Future GrowthAlamar Biosciences 過去の業績過去 基準チェック /06Alamar Biosciencesの収益は年間平均-3%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.5% 134%割合で 増加しています。主要情報-3.01%収益成長率6.69%EPS成長率Life Sciences 業界の成長21.51%収益成長率134.03%株主資本利益率-76.39%ネット・マージン-49.89%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.お知らせ • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026すべての更新を表示Recent updatesライブニュース • Jun 04Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.お知らせ • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.お知らせ • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alphaお知らせ • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering収支内訳Alamar Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:ALMR 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2687-43434231 Dec 2574-30363731 Dec 2425-461939質の高い収益: ALMRは現在利益が出ていません。利益率の向上: ALMRは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ALMRは株式公開されてから 3 年未満しか経っていないため、過去 5 年間の前年比収益成長率がプラスであったかどうかを判断できません。成長の加速: ALMRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ALMRは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 5.2% ) と比較することは困難です。株主資本利益率高いROE: ALMRは現在利益が出ていないため、自己資本利益率 ( -76.39% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 23:54終値2026/07/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alamar Biosciences, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Michael RyskinBofA Global ResearchCasey WoodringJ.P. MorganPuneet SoudaLeerink Partners LLC2 その他のアナリストを表示
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
お知らせ • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
ライブニュース • Jun 04Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.
お知らせ • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
お知らせ • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha
お知らせ • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering